title: High-dose cytosine arabinoside-induced symptomatic bradycardia.
abstract: Cardiac complications of high-dose cytosine arabinoside (HiDAC), although rare, predominantly include pericarditis, pericardial effusion and cardiomyopathy (with concurrent use of cyclophosphamide). Clinically significant arrhythmias associated with HiDAC, although reported in the literature, are rare. The following case report has for the first time used the Naranjo Scale to document a high-probability association (definite adverse drug reaction) of cytarabine with symptomatic sinus bradycardia.
authors.affiliation: aDepartment of Internal Medicine bSection of Hematology and Oncology cSection of Cardiovascular Diseases, University of Oklahoma, Oklahoma City, Oklahoma, USA.
authors.forename: Siddharth A
authors.initials: SA
authors.lastname: Wayangankar
authors.forename: Bhavin C
authors.initials: BC
authors.lastname: Patel
authors.forename: Hiral D
authors.initials: HD
authors.lastname: Parekh
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Holter
authors.forename: Ralph
authors.initials: R
authors.lastname: Lazzara
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D001919:Bradycardia / Q000139:chemically induced* / Q000175:diagnosis* / Q000503:physiopathology; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008875:Middle Aged
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine